Entellus Medical (NSDQ:ENTL) said today that it closed its approximately $81 million acquisition of Spirox and its Latera absorbable nasal implant. In the deal, Entellus paid $25 million in cash and issued approximately 3.4 million shares of Entellus common stock, which close at $16.51 the day before the deal was announced on July 7, putting the stock […]
Entellus Medical (NSDQ:ENTL) said today that it inked a deal worth some $81 million to acquire Spirox and its Latera absorbable nasal implant. The deal calls for Entellus to pay $25 million in cash and 3.4 million shares of its own stock for Redwood City, Calif.-based Spirox, which won 510(k) clearance from the FDA for the Latera […]
Spirox today released 1-year data from the 1st-in-human study of its Latera absorbable nasal implant designed to support nasal cartilage and prevent nasal valve collapse, which can contribute to nasal obstruction. Results from the study were published in the April issue of the journal Facial Plastic Surgery. Data from the study indicated that patients treated […]
Spirox on Monday released 1-year results from a multi-center study of its Latera absorbable nasal implant, touting a significant reduction in nasal obstruction symptoms in patients with nasal valve collapse. Results from the study were presented at the 2016 Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery this week. “Nasal valve collapse […]
Spirox said today it won FDA 510(k) clearance for its Latera absorbable nasal implant designed to support upper and lower Lateral nasal cartilages to prevent nasal valve constriction or collapse. The Menlo Park, Calif-based company said that the device has already been used in its 1st U.S. cases post-approval. “Latera is an important development for nasal obstruction […]
Skyline Medical CEO Kornberg steps down, Schwartz takes over as interim chief exec Skyline Medical said earlier this month that prez and CEO Joshua Kornberg has stepped away from his roles at the company, and is being replaced by Carl Schwartz who will serve as interim chief executive. Prior to his time at Skyline, Schwartz served […]
Spirox said today that it closed the books on a Series C round worth $45 million for the new device it’s developing to treat nasal obstructions. Spirox, which pulled down an $18.5 million Series B nearly a year ago, said the latest round was led by private equity giant KKR and joined by new investor HealthQuest […]
April 17, 2015 by Scott Wooldridge
Spirox said this week that it nailed down an $18.5 million Series B round to back development and commercialization of its device to treat patients with nasal obstructions.
Venrock and Aisling Capital led the round for Menlo Park, Calif.-based Spirox, with existing investors Aperture Venture Partners, Correlation Ventures and Western Technology Investment also participating.